ARL 17477 dihydrochloride
Cat. No. 3319
Chemical Name: N-[4-[2-[[(3-Chlorophenyl)methyl]am
Biological ActivitySelective neuronal nitrogen oxide synthase (nNOS) inhibitor (IC50 values are 1 and 17 μM for nNOS and endothelial NOS respectively). Reduces ischemic cell damage after middle cerebral artery (MCA) occlusion in rats. Displays a synergistic neuroprotective effect when combined with either an NMDA or AMPA receptor antagonist.
Licensing InformationSold with the permission of AstraZeneca UK Ltd.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
O'Neill et al (2000) ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia. Brain Res. 871 234. PMID: 10899290.
Hicks et al (1999) Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischaemia. Eur.J.Pharmacol. 381 113. PMID: 10554878.
Zhang et al (1996) ARL 17477, a potent and selective neuronal NOS inhibitor decreases infarct volume after transient middle cerebral artery occlusion in rats. J.Cereb.Flow Metab. 16 599.
If you know of a relevant reference for ARL 17477 dihydrochloride please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses ARL 17477 dihydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: ARL 17477 dihydrochloride, supplier, neuronal, nitric, oxide, synthase, nNOS, inhibitors, inhibits, ARL17477, Tocris Bioscience, nNOS Inhibitor products
Find multiple products by catalog number
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.